Access cutting-edge chronic lymphocytic leukemia treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access chronic lymphocytic leukemia specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chronic lymphocytic leukemia treatment provided free
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help t
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this chronic lymphocytic leukemia clinical trial in Birmingham, AL
If you're searching for chronic lymphocytic leukemia treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic lymphocytic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.